Characteristics of gastrointestinal hemorrhage associated with pancreatic cancer: A retrospective review of 246 cases

Wang,Yu; Yuan,Caijun; Liu,Xiaomei

doi:10.3892/mco.2015.563

Characteristics of gastrointestinal hemorrhage associated with pancreatic cancer: A retrospective review of 246 cases

Authors:
- Yu Wang
- Caijun Yuan
- Xiaomei Liu
View Affiliations

Affiliations: Department of Oncology, Graduate School of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China, Department of Oncology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China
Published online on: May 11, 2015 https://doi.org/10.3892/mco.2015.563
Pages: 902-908

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

While gastrointestinal (GI) hemorrhage is common in the general population, few studies have evaluated large numbers of GI hemorrhage patients with pancreatic cancer. The clinical features and potential risk factors of GI hemorrhage with pancreatic cancer was investigated in the present study and the effect of GI hemorrhage on survival rate was examined. Patients enrolled in the present study had pathologically proven pancreatic cancer, and received treatment between August 2006 and 2012. Their medical records were retrospectively reviewed. The data for the present study were obtained from a review of 246 patients with pancreatic cancer (average age, 63.4±10.92 years; 190 male cases, 56 female cases). In addition, 73 cases had stage I‑II, 173 had stage III‑IV, and only 67 cases (27.2%) were candidates for curative pancreatectomy. Among them, 32 cases (13.0%) were clinically diagnosed with GI hemorrhage. A total of 24 cases were male patients and the other 8 cases were female, the cases of hemorrhage history and alcoholism were 2 and 29 cases, respectively. The major initial clinical symptoms of GI hemorrhage included 18 patients with melena or blood stool (56.25%), 9 with haematemesis (28.13%), 3 with abdominal distention (9.37%) and 2 with stomach ache (6.25%). The independent risk factor for GI hemorrhage was tumor initial stage of IV. A continuous increase in carbohydrate antigen 19‑9 (CA19‑9) may be a warning of GI hemorrhage, particularly when it is >1,000 U/ml. The most frequent method of hemostasis was combination therapy (n=12, 37.5%). Only 3 cases (9.3%) of these 32 GI hemorrhage patients were blood stanched and only 10 patients (31.2%) received gastroscopy. The time from GI hemorrhage to fatality is extremely short (median 30 days, range from 1 h to 65 days), and the median overall survival time of the patients with GI hemorrhage was 9.0 months (range, 2.0‑16.0 months) and was significantly shorter than that of patients without GI hemorrhage [14.5 months (range, 0.5‑48.0 months)]. In conclusion, although GI hemorrhage was not common in patients with pancreatic cancer, it is critical. GI hemorrhage was controlled with endoscopic hemostasis. Clinicians should fully assess the risk factors of GI hemorrhage (such as alcohol, smoking, past hemorrhage history, initial stage, tumor location and CA19‑9 level at diagnosis of pancreatic cancer) when the pancreatic cancer patients were on admission, particularly for patients of the late stage, preventive measures should be investigated to reduce suffering.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
2	Olowokure O and Qi X: Pancreatic cancer: Current standards, working towards a new therapeutic approach. Expert Rev Anticancer Ther. 14:495–497. 2014. View Article : Google Scholar : PubMed/NCBI
3	Winek T, Hamre D, Mozell E and Vetto RM: Prognostic factors for survival after pancreaticoduodenectomy for malignant disease. Am J Surg. 159:454–456. 1990. View Article : Google Scholar : PubMed/NCBI
4	Rockey DC: To transfuse or not to transfuse in upper gastrointestinal hemorrhage? That is the question. Hepatology. 60:422–424. 2014. View Article : Google Scholar : PubMed/NCBI
5	Longstreth GF: Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: A population-based study. Am J Gastroenterol. 92:419–424. 1997.PubMed/NCBI
6	Longstreth GF: Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: A population-based study. Am J Gastroenterol. 90:206–210. 1995.PubMed/NCBI
7	Wollenman CS, Chason R, Reisch JS and Rockey DC: Impact of ethnicity in upper gastrointestinal hemorrhage. J Clin Gastroenterol. 48:343–350. 2014. View Article : Google Scholar : PubMed/NCBI
8	Fallah MA, Prakash C and Edmundowicz S: Acute gastrointestinal bleeding. Med Clin North Am. 84:1183–1208. 2000. View Article : Google Scholar : PubMed/NCBI
9	Greenspoon J, Barkun A, Bardou M, Chiba N, Leontiadis GI, Marshall JK, Metz DC, Romagnuolo J and Sung J: International Consensus Upper Gastrointestinal Bleeding Conference Group: Management of patients with nonvariceal upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 10:234–239. 2012. View Article : Google Scholar : PubMed/NCBI
10	Cooper GS, Chak A, Way LE, Hammar PJ, Harper DL and Rosenthal GE: Early endoscopy in upper gastrointestinal hemorrhage: Associations with recurrent bleeding, surgery and length of hospital stay. Gastrointest Endosc. 49:145–152. 1999. View Article : Google Scholar : PubMed/NCBI
11	Simoens M, Gevers AM and Rutgeerts P: Endoscopic therapy for upper gastrointestinal hemorrhage: A state of the art. Hepatogastroenterology. 46:737–745. 1999.PubMed/NCBI
12	Longstreth GF and Feitelberg SP: Outpatient care of selected patients with acute non-variceal upper gastrointestinal haemorrhage. Lancet. 345:108–111. 1995. View Article : Google Scholar : PubMed/NCBI
13	Silverstein FE, Gilbert DA, Tedesco FJ, Buenger NK and Persing J: The national ASGE survey on upper gastrointestinal bleeding. II. Clinical prognostic factors. Gastrointest Endosc. 27:80–93. 1981. View Article : Google Scholar : PubMed/NCBI
14	Laine L, Yang H, Chang SC and Datto C: Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 107:1190–1195; quiz 1196. 2012. View Article : Google Scholar : PubMed/NCBI
15	Charbonnet P, Toman J, Bühler L, Vermeulen B, Morel P, Becker CD and Terrier F: Treatment of gastrointestinal hemorrhage. Abdom Imaging. 30:719–726. 2005. View Article : Google Scholar : PubMed/NCBI
16	Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM and Sibbald WJ: The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 101:1644–1655. 1992. View Article : Google Scholar : PubMed/NCBI
17	Davenport RJ, Dennis MS and Warlow CP: Gastrointestinal hemorrhage after acute stroke. Stroke. 27:421–424. 1996. View Article : Google Scholar : PubMed/NCBI
18	Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S and Aikou T: Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 53:146–150. 2002. View Article : Google Scholar : PubMed/NCBI
19	Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, Chang FY, Lee SD and Yen SH: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys. 57:98–104. 2003. View Article : Google Scholar : PubMed/NCBI
20	Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 19:1592–1599. 2008. View Article : Google Scholar : PubMed/NCBI
21	Lee KJ, Kim HM, Jung JW, Chung MJ, Park JY, Bang S, Park SW, Lee WJ, Seong JS and Song SY: Gastrointestinal hemorrhage after concurrent chemoradiotherapy in locally advanced pancreatic cancer. Gut Liver. 7:106–111. 2013. View Article : Google Scholar : PubMed/NCBI
22	Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, et al: Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 52:1293–1302. 2002. View Article : Google Scholar : PubMed/NCBI
23	Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F and Azria D: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: A qualitative systematic review. J Clin Oncol. 27:2269–2277. 2009. View Article : Google Scholar : PubMed/NCBI
24	Cheung J, Yu A, LaBossiere J, Zhu Q and Fedorak RN: Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. Gastrointest Endosc. 71:44–49. 2010. View Article : Google Scholar : PubMed/NCBI
25	Toke AB: GI bleeding risk in patients undergoing dialysis. Gastrointest Endosc. 71:50–52. 2010. View Article : Google Scholar : PubMed/NCBI